| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0df29899e58d1eda4f6c772d002a9a9b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2001-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e03c913ae60ee85f782bd935a19fd808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a186da212b79ec85bb61120f99dfc4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c78d9a40c2cddfd7af841894494e5277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa4a9089b8bf72a94d555525fe358004 |
| publicationDate |
2006-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2286769-C2 |
| titleOfInvention |
Combination of therapeutical agents (for example, chloropromazine and pentamidine) for treating neoplastic disorders |
| abstract |
FIELD: oncology. n SUBSTANCE: group of inventions is provided concerning a method of treating a patient with cancer and envisaging administration of chloropromazine and pentamidine simultaneously or consecutively with interval within 14 days in quantities large enough to inhibit growth of the cancer, or in the form of pharmaceutical composition containing indicated agents in quantities, which jointly reduce proliferation of the indicated cancer cells. Pharmaceutical composition itself designed to indicated treatment and pharmaceutical kit are also disclosed. Proposed therapeutical agents separately do not show any antiproliferative effects. n EFFECT: achieved synergetic antiproliferative effect in absence of toxicity regarding normal cells. n 17 cl, 1 tbl, 2 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2530651-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2608388-C2 |
| priorityDate |
2000-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |